Fennec Pharmaceuticals Inc.

FENC

CA31447P1009

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:29:46 30/05/2024 am IST			5-day change	1st Jan Change
7.155 ^USD	+1.78%		-0.49%	-36.23%

15/05	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating	MT
14/05	Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024

Shubh Goel to Depart Fennec Pharmaceuticals Inc. as Chief Commercial Officer in Late February 2022

January 31, 2022 at 04:30 pm IST

Fennec Pharmaceuticals Inc. announced that Shubh Goel, the company's chief commercial officer, has tendered her resignation and will depart Fennec in late February 2022.

Latest news about Fennec Pharmaceuticals Inc.

HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating	15/05	MT
Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue	14/05	MT
Fennec Pharmaceuticals Brief: Company Says Has Approximately US$51 Million in Cash, Cash Equivalents, and Investment Securities	14/05	MT
Fennec Pharmaceuticals Brief: Achieved Q1 2024 Total Net Revenues of US$25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction	14/05	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	23/04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	19/04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	17/04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	06/04	MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating	04/04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	04/04	MT
Wedbush on Fennec's Q4	22/03	MT
Transcript : Fennec Pharmaceuticals Inc., 2023 Earnings Call, Mar 21, 2024	21/03
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	21/03	MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	21/03	MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	21/03	MT
North American Morning Briefing : Investors -2-	21/03	DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	21/03	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03	CI
Wedbush on Fennec's Deal for Pedmarqsi in EU	18/03	MT
Sector Update: Health Care Stocks Steady Premarket Monday	18/03	MT
Sector Update: Health Care	18/03	MT
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ	18/03	MT

Chart Fennec Pharmaceuticals Inc.

Duration

Period

More charts

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Sector

Biotechnology & Medical Research

Calendar

25/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Fennec Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.15 USD

Average target price

16.83 USD

Spread / Average Target

+135.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FENNEC PHARMACEUTICALS INC.	-36.23%	195M
VERTEX PHARMACEUTICALS INCORPORATED	+8.38%	114B
REGENERON PHARMACEUTICALS, INC.	+10.13%	104B
BIONTECH SE	-11.69%	22.5B
ARGENX SE	+1.16%	22.57B
GENMAB A/S	-11.16%	17.95B
WUXI APPTEC CO., LTD.	-41.90%	16.48B
BEIGENE, LTD.	-16.00%	15.82B
NEUROCRINE BIOSCIENCES, INC.	+2.28%	13.55B
SAREPTA THERAPEUTICS, INC.	+20.54%	10.99B

Bio Therapeutic Drugs

Fennec Pharmaceuticals Inc.

Equities

FENC

CA31447P1009

Biotechnology & Medical Research

Shubh Goel to Depart Fennec Pharmaceuticals Inc. as Chief Commercial Officer in Late February 2022

Latest news about Fennec Pharmaceuticals Inc.

Chart Fennec Pharmaceuticals Inc.

Company Profile

Income Statement Evolution

Ratings for Fennec Pharmaceuticals Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs